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INTRODUCTION
Synthetic cannabinoid (SC) use has gained in popularity over 
the last decade in part due to ease of obtainability, perceived 
safety, and the ability to avoid detection on routine urine drug 
tests.1 Once thought as a “legal high”, users generally believe 
the effects and risks of SC to be similar to cannabis, if not safer. 
Although sparse, the medical literature has been increasing 
with reports of severe psychosis associated with SC use.1-7 How-
ever, little is known about the duration of the effects. We report 
a unique case of prolonged psychosis after chronic use of SC.
CASE REPORT
An 18-year-old male presented to the emergency depart-
ment (ED) with his parents after exhibiting bizarre behav-
ior. In the ED, he presented with delusional thinking (e.g., 
government agents spying on him, mother poisoning his 
food), hearing voices, and responding to internal stimuli. 
His parents reported that symptoms started approximate-
ly two months prior after the patient relapsed and began 
smoking “K2” (a SC). He was admitted to the inpatient psy-
chiatry unit and started on risperidone 1 mg twice daily.
He had experienced a similar episode eight months prior 
resulting in a 12-day hospitalization, considered to be sec-
ondary to chronic SC and marijuana use. He was treated and 
discharged on olanzapine and lithium. However, lithium was 
discontinued secondary to elevated thyroid stimulating hor-
mone and olanzapine was discontinued a few months later due 
to continued stability and concerns regarding weight gain. He 
had no previous psychiatric history aside from mild chronic 
anxiety. Family history included a sibling with substance use 
disorder and mother with anxiety disorder. There was no 
family history of any psychotic disorder (e.g., schizophrenia). 
On his admission, physical examination and baseline labo-
ratory results (complete blood count, metabolic panel, and 
thyroid stimulating hormone) were unremarkable, including 
a urine drug screen which was negative. Blood alcohol level 
was not done at that time. He subsequently admitted to smok-
ing “K2” chronically over the last two years. On day two of 
hospitalization, risperidone was increased to 4 mg/day with 
the addition of benztropine for extrapyramidal side effects. 
Over the next five days, he markedly improved and discharge 
planning was in process. However, on day seven, his psycho-
sis returned accompanied by severe paranoia and an intense 
fear of dying. Risperidone was increased to 5 mg/day. Over 
the next eight days, his symptoms waxed and waned with 
periods of improvement followed by bizarre behavior includ-
ing agitation, running into walls, and head banging requir-
ing physical restraints. During one episode, he experienced 
diaphoresis, muscle rigidity, elevated temperature (37.8oC) 
and tachycardia (pulse 145). Throughout these periods of agi-
tation, he was administered haloperidol (which resulted in a 
dystonic reaction), fluphenazine, or chlorpromazine along with 
lorazepam. Subsequently, risperidone was increased to 6 mg/
day. Both magnetic resonance imaging and electroencephalo-
gram were performed to rule out any acute intracranial pathol-
ogy or epileptic activity; however, both studies were negative. 
On day 15, divalproex sodium was started. It was switched 
three days later to lithium 600 mg/day due to elevated liv-
er function tests. Shortly after starting lithium, the patient 
achieved sustained improvement without evidence of psy-
chosis or agitation. He was discharged on day 26 taking 
risperidone 6 mg/day and lithium carbonate 600 mg/day.
DISCUSSION
Treatment of SC intoxication or toxicity can be challenging 
for clinicians due to the unknown effects of these agents. The 
most common active ingredient in SC is JWH-018, although 
products such as “K2”, “Spice”, and others may contain a 
blend of different SC (JWH-073, JWH-175 or similar).8 The 
potency of SC is considered to be higher than tetrahydrocan-
nabinol (THC) due to its full agonist effects on marijuana CB1 
receptor compared to THC which is a weak partial agonist.8,9 
Common symptoms of SC use include euphoria, anxiety, 
irritability, and tachycardia.8 However, increasing reports 
of psychosis and paranoia are emerging in the literature.1-7 A 
dose-response effect is theorized, meaning the heavier the 
use of SC, the more likely that psychotic effects will occur.8 
Unfortunately, duration and treatment of psychosis sec-
ondary to SC remains unclear. Most case reports described 
psychosis as acute in onset, with symptoms resolving with-
in 24 hours to one week requiring only supportive care.1,3,5,6 
However, in our patient, symptoms continued for almost 
one month. Only two case series were found describing psy-
chosis lasting greater than two weeks in duration.3,7 Van der 
Veer et al.7 reported a case series of three patients all requiring 
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at least two-weeks of hospitalization following SC use. 
Their patients were treated with haloperidol or risperi-
done for their psychotic symptoms, and all patients had 
some psychotic symptoms present on discharge. Moreover, 
Hurst3 reported psychotic symptoms lasting five months 
in three previously healthy males aged 21-25 after us-
ing SC. Treatment of their symptoms was not discussed. 
There are no treatment recommendations for 
SC intoxication. Treatment of psychosis from SC 
commonly has been treated with haloperidol, 
olanzapine, or risperidone, while benzodiazepines are used reg-
ularly for supportive care for acute agitation and restlessness.2,5-7 
The majority of case reports or series of patients experiencing 
psychotic symptoms with SC are less than 30 years of age, which 
coincides with the usual age of onset of thought disorders such as 
schizophrenia.2-5,7 SC may unmask symptoms of schizophrenia 
and this cannot be ruled out in our patient. Long term follow-up 
with our patient was needed to differentiate between a primary 
thought disorder versus substance induced psychotic disorder. 
Our patient admitted to heavy SC use. Thus, we did not test 
specifically for the presence of SC. A few immunoassays have 
been developed to test for major metabolites of JWH-018.10,11 
However, testing in the urine is difficult due to the constantly 
changing composition of SC. Clinicians may consider urine test-
ing for SC in patients presenting with psychosis though these 
tests are not routinely available at most medical centers. Sam-
ples generally have to be sent to an outside laboratory, result-
ing in delayed results, especially in the ED setting. Most often, 
clinicians will rely on patient or collateral information of SC 
use and utilize clinical judgment regarding SC consumption. 
 The long lasting presence of psychotic symptoms in our pa-
tient was concerning. This case highlighted the unknown risks, 
dangers, and treatment challenges in patients using SC.   With 
the increasing popularity of SC among adolescents and young 
adults, further research is needed to determine behavioral, cog-
nitive, psychological, and long-term effects of SC.  Additional 
research and literature to describe the effects of SC can edu-
cate the public and health-care professionals about its dangers.
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